Transgene Valuation
| TRGNF Stock | USD 1.59 0.00 0.00% |
Based on Macroaxis valuation methodology, the company appears to be fairly valued. Transgene SA has a current Real Value of $1.59 per share. The regular price of the company is $1.59. Our model measures the value of Transgene SA from inspecting the company fundamentals such as Return On Equity of -0.36, operating margin of (1.39) %, and Shares Outstanding of 100.2 M as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Transgene's price fluctuation is very steady at this time. Calculation of the real value of Transgene SA is based on 3 months time horizon. Increasing Transgene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Transgene pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Transgene SA. Since Transgene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Transgene Pink Sheet. However, Transgene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.59 | Real 1.59 | Hype 1.59 | Naive 1.59 |
The real value of Transgene Pink Sheet, also known as its intrinsic value, is the underlying worth of Transgene SA Company, which is reflected in its stock price. It is based on Transgene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Transgene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Transgene SA helps investors to forecast how Transgene pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Transgene more accurately as focusing exclusively on Transgene's fundamentals will not take into account other important factors: Transgene Total Value Analysis
Transgene SA is at this time estimated to have takeover price of 152.15 M with market capitalization of 212.74 M, debt of 0, and cash on hands of 49.57 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Transgene fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
152.15 M | 212.74 M | 0 | 49.57 M |
Transgene Investor Information
The company has price-to-book ratio of 0.02. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Transgene SA recorded a loss per share of 0.23. The entity had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Transgene's historical financial statements, Transgene SA is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Transgene Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Transgene has an asset utilization ratio of 9.81 percent. This implies that the Company is making $0.0981 for each dollar of assets. An increasing asset utilization means that Transgene SA is more efficient with each dollar of assets it utilizes for everyday operations.Transgene Ownership Allocation
Transgene SA shows a total of 100.2 Million outstanding shares. About 98.3 % of Transgene outstanding shares are held by general public with 1.7 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Transgene Profitability Analysis
The company reported the revenue of 9.99 M. Net Loss for the year was (19.54 M) with loss before overhead, payroll, taxes, and interest of (15.87 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Transgene's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Transgene and how it compares across the competition.
About Transgene Valuation
The pink sheet valuation mechanism determines Transgene's current worth on a weekly basis. Our valuation model uses a comparative analysis of Transgene. We calculate exposure to Transgene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Transgene's related companies.Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people.
8 Steps to conduct Transgene's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Transgene's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Transgene's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Transgene's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Transgene's revenue streams: Identify Transgene's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Transgene's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Transgene's growth potential: Evaluate Transgene's management, business model, and growth potential.
- Determine Transgene's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Transgene's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Transgene Growth Indicators
Investing in growth stocks can be very risky. If the company such as Transgene does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 83.8 M | |
| Retained Earnings | -50.6 M |
Complementary Tools for Transgene Pink Sheet analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |